Drug intelligence / Profile preview

BA-2017

Development stage: Preclinical
Lead developer: BioArctic
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular, Subcutaneous

Overview

BA-2017 is an experimental second-generation vaccine being developed for the treatment of Parkinson's disease and other synucleinopathies. Developed by BioArctic, the vaccine is designed to stimulate the body's own immune system to produce specific antibodies that target and neutralize toxic aggregated forms of alpha-synuclein, such as oligomers and protofibrils. By selectively targeting these pathological species while sparing physiological monomeric alpha-synuclein, BA-2017 aims to slow or halt the progression of neurodegeneration. The project leverages BioArctic's expertise in protein misfolding and immunotherapy, following the development of their earlier alpha-synuclein antibody programs.

Other names: BioArctic alpha-synuclein vaccine

Targets

SNCA (Alpha-synuclein)

Beyond the preview

Go deeper on BA-2017.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BA-2017.

Explore the full profile